Is Wolverine (BPC-157 + TB-500) approved or legal?

Neither BPC-157 nor TB-500 is FDA-approved for human use, and the blend has no recognized human dosing standard. Both are sold for research purposes only and sit in a regulatory gray zone; the FDA has not authorized them for compounding. TB-500 is also banned at all times by WADA, and BPC-157 is on the WADA prohibited list. It is not legal to market for human consumption.

What is the half-life of the Wolverine stack?

Both peptides have short plasma half-lives: BPC-157 is roughly 15-30 minutes in rodent studies, and TB-500 is on the order of minutes to about 1-3 hours. However, both show a pharmacokinetic/pharmacodynamic disconnect, meaning their downstream biological effects appear to persist far longer than the peptides remain in the blood.

Is there human clinical evidence that the combination works?

No. There are no controlled human trials of the BPC-157 + TB-500 blend. The supporting data is almost entirely preclinical (animal and in-vitro) and component-specific. Claims of synergy are mechanistic hypotheses and user anecdotes, not proven human outcomes.

What dosing do people report using?

Anecdotally and for research reference only (not medical advice), community guides describe BPC-157 around 250-500 mcg/day with TB-500 in a loading phase of about 2-5 mg twice weekly followed by ~2 mg weekly maintenance, or a pre-blended 1:1 vial at ~0.5-2.0 mg/day over an 8-12 week cycle. These are unverified, vary widely, and are not standardized.

What are the main safety concerns?

Human safety data is very limited. Reported anecdotal effects include injection-site irritation, fatigue, lightheadedness, and headache. A theoretical concern is that angiogenic, proliferative peptides could promote growth of existing tumors. Unregulated research-chemical purity is also a significant risk. Consult a qualified clinician before considering any peptide.

Blend

Wolverine (BPC-157 + TB-500)

Also known as: Wolverine stack, Wolverine blend, BPC-157 + TB-500 stack

Research blend of BPC-157 and TB-500 explored for tissue repair. Evidence is largely preclinical; combination synergy in humans is unproven.

Last updated July 11, 2026

Buy Wolverine (BPC-157 + TB-500)

What's in this blend

BPC-157 — 10mg (details)
TB-500 — 10mg (details)

Overview

The "Wolverine" stack pairs two research peptides, BPC-157 (a synthetic gastric pentadecapeptide) and TB-500 (a synthetic fragment of thymosin beta-4), that have each been studied separately for soft-tissue repair. The combination is named for its popular association with rapid healing, but it is important to note that no human clinical trial has tested the blend itself. Individually, both peptides have a substantial preclinical (animal and in-vitro) literature touching on angiogenesis, cell migration, and collagen-related processes. The proposed rationale for combining them is that they act through largely non-overlapping pathways: BPC-157 is associated with VEGFR2-Akt-eNOS signaling and fibroblast activity, while TB-500 acts mainly through actin regulation and progenitor-cell recruitment. Direct human evidence is thin. A 2025 systematic review of BPC-157 in orthopaedic sports medicine found that of 36 included studies, only 1 was a clinical study, with the remainder preclinical animal models. TB-500 likewise lacks human efficacy trials and is banned in sport. Neither component is FDA-approved for human use, and both are sold for research purposes only. Any reported "protocols" are anecdotal and should be treated as research reference material, not medical guidance.

How it works

The two components are thought to address complementary stages of tissue repair through distinct mechanisms. BPC-157 has been shown in preclinical models to upregulate VEGF and VEGFR2 and to stimulate the VEGFR2-Akt-eNOS pathway, promoting angiogenesis; it also enhances tendon-fibroblast survival and migration (via the FAK-paxillin pathway) and increases growth-hormone-receptor expression in fibroblasts. TB-500 (thymosin beta-4 fragment) works primarily by sequestering monomeric G-actin, regulating the actin cytoskeleton that underlies cell migration, endothelial tube formation, angiogenesis, and recruitment of progenitor cells, along with anti-inflammatory signaling. The combined hypothesis is that TB-500 mobilizes and migrates cells while BPC-157 supports vascularization and fibroblast/collagen activity, but this synergy has not been validated in controlled human studies.

Researched effects

Preclinical Accelerated tendon, ligament, and muscle healing in animal models (BPC-157)
Preclinical Modulation of angiogenesis and VEGF signaling supporting tissue repair (BPC-157)
Preclinical Enhanced cell migration, re-epithelialization, and wound healing (TB-500 / thymosin beta-4)
Preclinical Anti-inflammatory effects supporting earlier repair phases (TB-500)
Anecdotal Faster recovery from injuries and reduced joint/soft-tissue pain when stacked
Anecdotal Synergistic, broader-spectrum healing from combining the two peptides

Evidence levels: Clinical (human trials) · Preclinical (animal/lab) · Anecdotal (community-reported).

Dosing reference

For research reference only — not a recommendation.

Clinical / studied dosing

No established clinical dosing in humans. There are no controlled human trials of the BPC-157 + TB-500 blend, and neither peptide has an approved human dosing protocol or USP/NF monograph.

Community-reported dosing (anecdotal)

Anecdotal and research-reference-only; not medical advice. Community write-ups and forum guides (e.g., r/Peptides discussions and peptide protocol sites) commonly describe two patterns. (1) Separate vials: BPC-157 roughly 250-500 mcg/day subcutaneously, often near the injury site, alongside TB-500 in a loading phase of ~2-5 mg twice weekly for ~4 weeks, then a maintenance phase of ~2 mg once weekly, over an 8-12 week cycle. (2) A pre-blended 1:1 vial dosed at ~0.5-2.0 mg total per day for 6-12 weeks. These figures are self-reported, vary widely, are not standardized or verified, and reflect research-chemical use rather than any approved regimen.

Half-life: BPC-157: very short plasma half-life (~15-30 min in rodents); TB-500: short plasma half-life (~minutes to ~1-3 hours). Both show a PK/PD disconnect, with downstream biological effects persisting far longer than plasma presence.
Routes: subcutaneous, intramuscular

Safety & side effects

Human safety data for either peptide, and especially for the combination, is very limited; most safety inferences come from animal studies and anecdotal reports. Commonly reported anecdotal effects include injection-site irritation, fatigue or lethargy (often attributed to TB-500), lightheadedness, and headache. Because both peptides influence angiogenesis and cell proliferation, a theoretical concern is the potential to promote growth of existing or undetected tumors; this has not been well characterized in humans. Product purity is a major real-world risk, as research-chemical peptides are unregulated and may be mislabeled or contaminated. Neither peptide is FDA-approved for human use. TB-500 is banned at all times by WADA (Section S2); BPC-157 is also on the WADA prohibited list. Individuals with cancer history, pregnancy, or on other medications should be especially cautious. This is informational only and not medical advice.

Research summary

The evidence base for the Wolverine stack is overwhelmingly preclinical and component-specific rather than blend-specific. BPC-157 has a sizable rodent and in-vitro literature suggesting effects on angiogenesis (VEGFR2-Akt-eNOS), tendon-fibroblast survival and migration (FAK-paxillin), and gastrointestinal and musculoskeletal healing. A 2025 systematic review of BPC-157 in orthopaedic sports medicine screened 544 articles and included 36 studies, of which only 1 was a human clinical study and the rest were preclinical animal models, confirming that controlled human efficacy data is essentially absent. TB-500, a thymosin beta-4 fragment, has consistent preclinical support for actin-mediated cell migration, angiogenesis, and accelerated wound re-epithelialization, but likewise lacks human efficacy trials for the indications it is marketed toward. Crucially, the combination itself has not been tested in controlled human studies; claims of synergy are mechanistic hypotheses and user anecdotes. The two peptides plausibly target complementary, non-overlapping pathways, which is the basis for stacking them, but this remains unproven in humans. Given the absence of clinical efficacy and safety data, regulatory gray-zone status, WADA prohibition of TB-500, and quality concerns with research-chemical sourcing, the honest position is cautious: promising preclinical signals, no human proof of the blend, and real unknowns around long-term safety.

FAQ

Is Wolverine (BPC-157 + TB-500) approved or legal?: Neither BPC-157 nor TB-500 is FDA-approved for human use, and the blend has no recognized human dosing standard. Both are sold for research purposes only and sit in a regulatory gray zone; the FDA has not authorized them for compounding. TB-500 is also banned at all times by WADA, and BPC-157 is on the WADA prohibited list. It is not legal to market for human consumption.
What is the half-life of the Wolverine stack?: Both peptides have short plasma half-lives: BPC-157 is roughly 15-30 minutes in rodent studies, and TB-500 is on the order of minutes to about 1-3 hours. However, both show a pharmacokinetic/pharmacodynamic disconnect, meaning their downstream biological effects appear to persist far longer than the peptides remain in the blood.
Is there human clinical evidence that the combination works?: No. There are no controlled human trials of the BPC-157 + TB-500 blend. The supporting data is almost entirely preclinical (animal and in-vitro) and component-specific. Claims of synergy are mechanistic hypotheses and user anecdotes, not proven human outcomes.
What dosing do people report using?: Anecdotally and for research reference only (not medical advice), community guides describe BPC-157 around 250-500 mcg/day with TB-500 in a loading phase of about 2-5 mg twice weekly followed by ~2 mg weekly maintenance, or a pre-blended 1:1 vial at ~0.5-2.0 mg/day over an 8-12 week cycle. These are unverified, vary widely, and are not standardized.
What are the main safety concerns?: Human safety data is very limited. Reported anecdotal effects include injection-site irritation, fatigue, lightheadedness, and headache. A theoretical concern is that angiogenic, proliferative peptides could promote growth of existing tumors. Unregulated research-chemical purity is also a significant risk. Consult a qualified clinician before considering any peptide.

References

All content is for research and educational use only and is not medical advice. Products are sold for laboratory research only and are not for human consumption.